MedTrace Logo

Six-months Versus Nine-months ATT for Ocular TB

NCT06613919 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-09-26

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if 6-months anti-TB therapy is not worse than 9-months therapy for the treatment of tubercular posterior uveitis. The main questions it aims to answer are:

Does six-month therapy work as well as the nine-month therapy? Do any of the specific phenotypes of TB posterior uveitis respond better to any specific duration of anti-TB therapy?

Participants:

Took the standard dose of six- or nine-month ATT for TB posterior uveitis Visit the clinic as advised for checkups and tests

Conditions

  • Tuberculosis (TB)
  • Uveitis
  • Retinal Vasculitis
  • Choroiditis

Interventions

DRUG

Anti-Tuberculosis Treatment

Standard, weight adjusted anti-TB therapy for six months

DRUG

Anti-Tuberculosis Treatment

Standard, weight-adjusted anti-TB therapy for nine months

Sponsors & Collaborators

  • L.V. Prasad Eye Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • Burma
  • India
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613919 on ClinicalTrials.gov